#1 Clinical Trials Search in Europe

Letrozole

Letrozole is a medication that has been extensively studied in clinical trials for various medical conditions, primarily breast cancer and fertility treatments. This article summarizes key findings from several clinical trials investigating the use of letrozole in different contexts, providing insights into its effectiveness, safety, and potential applications.

Table of Contents

What is Letrozole?

Letrozole is a medication primarily used in the treatment of breast cancer. It belongs to a class of drugs called aromatase inhibitors. Letrozole is also known by the brand name Femara[1]. This medication is typically prescribed for postmenopausal women with a specific type of breast cancer known as hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer[1].

How Letrozole Works

Letrozole works by reducing the amount of estrogen in the body. It does this by blocking an enzyme called aromatase, which is responsible for producing estrogen. By lowering estrogen levels, letrozole can slow down or stop the growth of certain types of breast cancer cells that rely on estrogen to grow[2].

Conditions Treated with Letrozole

While letrozole is primarily used for breast cancer treatment, research is ongoing to explore its potential in treating other conditions. Here are the main conditions for which letrozole is used or being studied:

  • Advanced Breast Cancer: Letrozole is approved for treating postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer[1]. This type of breast cancer has receptors that are sensitive to hormones like estrogen, but does not have high levels of a protein called HER2 on the cancer cells.
  • Endometrial Cancer: Some studies are investigating the use of letrozole in treating advanced or recurrent endometrial cancer. Endometrial cancer is a type of cancer that begins in the lining of the uterus[3].
  • Ovarian Cancer: Research is being conducted to evaluate the effectiveness of letrozole in treating heavily pretreated recurrent ovarian cancer[4]. Ovarian cancer is a type of cancer that begins in the ovaries.

Dosage and Administration

Letrozole is typically taken orally in tablet form. The standard dosage for breast cancer treatment is 2.5 mg once daily[1]. It’s usually taken continuously, meaning you take it every day without breaks. Your doctor will determine the appropriate dosage and duration of treatment based on your specific condition and response to the medication.

Combination Therapies

In some cases, letrozole may be used in combination with other medications to enhance its effectiveness. One such combination that has been studied is letrozole with palbociclib (also known as PD-0332991 or Ibrance)[2]. Palbociclib is a drug that works by blocking certain proteins in cancer cells, potentially making letrozole more effective. This combination is being studied for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.

Side Effects and Safety

Like all medications, letrozole can cause side effects. Common side effects may include:

  • Hot flashes
  • Joint pain
  • Fatigue
  • Headache
  • Nausea

More serious side effects can occur, but they are less common. These may include an increased risk of osteoporosis (bone thinning) and cardiovascular events. Your doctor will monitor you closely for any side effects and adjust your treatment if necessary[2].

Ongoing Research

Several clinical trials are currently underway to further investigate the use of letrozole in various settings:

  • Combination therapy with new drugs: Studies are exploring the combination of letrozole with newer drugs like PF-07220060 for breast cancer treatment[5].
  • Expanded access studies: These studies aim to provide access to letrozole for patients who might benefit from it but don’t qualify for other clinical trials[6].
  • Use in other cancers: As mentioned earlier, research is ongoing to evaluate the effectiveness of letrozole in endometrial and ovarian cancers[3][4].

It’s important to note that while these studies show promise, more research is needed to fully understand the potential benefits and risks of letrozole in these new applications.

Use of Letrozole Key Findings Dosage
Breast Cancer Treatment Effective as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer; various treatment durations studied (2-5+ years) 2.5 mg daily
Fertility Treatment Used for ovulation induction in IVF; may help maintain lower estrogen levels during stimulation 2.5-7.5 mg daily, depending on protocol
Neoadjuvant Therapy Studied in combination with other drugs (e.g., Avastin) for pre-operative treatment of breast cancer 2.5 mg daily
Uterine Leiomyosarcoma Under investigation for newly diagnosed stage I and II leiomyosarcoma 2.5 mg daily

FAQ

  • What is letrozole and how does it work? Letrozole is an aromatase inhibitor that blocks the production of estrogen in the body. It works by inhibiting the enzyme aromatase, which is responsible for converting androgens into estrogens. This mechanism makes it useful in treating hormone-sensitive breast cancers and in certain fertility treatments.
  • How is letrozole used in breast cancer treatment? Letrozole is commonly used as an adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer. It can be given after initial treatment with tamoxifen or as a primary treatment. Clinical trials have explored different durations and regimens of letrozole treatment to determine the most effective approach.
  • Can letrozole be used in fertility treatments? Yes, letrozole has been studied for use in fertility treatments, particularly for ovulation induction. It can be used to stimulate egg development in women undergoing in vitro fertilization (IVF) or as a treatment for infertility. Some trials have investigated its use in combination with other fertility medications.
  • What are the potential side effects of letrozole? Common side effects of letrozole may include hot flashes, joint pain, fatigue, and headaches. In fertility treatments, it may cause changes in ovarian function. Long-term use in breast cancer treatment may lead to bone density loss. Always consult with a healthcare provider about potential side effects.
  • How long is letrozole typically used in breast cancer treatment? The duration of letrozole treatment can vary. Some clinical trials have investigated standard treatment durations of 2-3 years, while others have explored extended treatment periods of up to 5 years or more. The optimal duration may depend on individual patient factors and response to treatment.

Ongoing Clinical Trials on Letrozole

  • Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria France Germany Hungary +6

  • Study Comparing Chemotherapy and Abemaciclib with Hormone Therapy for Patients with ER+ HER2- Metastatic Breast Cancer with Visceral Involvement

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Palbociclib and Drug Combination for Patients with Hormone Receptor Positive, HER2-Positive Metastatic Breast Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Portugal Spain

  • Study of Ribociclib and Letrozole for Patients with High-Risk Estrogen Receptor-Positive, HER2-Negative Breast Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    France Spain

  • Study Comparing Two Treatment Sequences of CDK4/6 Inhibitors (Abemaciclib, Palbociclib, or Ribociclib) in Hormone Receptor Positive Advanced Breast Cancer

    Not recruiting

    1 1 1 1
    Investigated drugs:
    The Netherlands

  • Evaluation of Abemaciclib with Standard Endocrine Therapy in Patients with High Risk, Early Stage, Hormone Receptor Positive, HER2 Negative Breast Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +10

  • Study on the Effectiveness and Safety of Cyclophosphamide Monohydrate and Drug Combination for Patients with Persistent or Recurrent Rare Epithelial Ovarian Tumors

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Italy Spain

  • Study of Palbociclib as an Alternative to Chemotherapy for Older Patients with High-Risk Early Breast Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium France Germany Italy Poland Portugal +1

  • Study of tucatinib, pertuzumab and trastuzumab combination for patients with HER2-positive metastatic breast cancer who have brain metastases after local therapy

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Alpelisib with Fulvestrant or Letrozole for Patients with Advanced Breast Cancer and PIK3CA Mutation After Previous Treatments

    Not recruiting

    1 1 1
    Investigated drugs:
    Denmark Italy

Glossary

  • Aromatase inhibitor: A type of drug that lowers estrogen levels in the body by blocking the enzyme aromatase, which is responsible for producing estrogen.
  • Adjuvant therapy: Additional cancer treatment given after the primary treatment to lower the risk of cancer recurrence.
  • Hormone receptor-positive breast cancer: A type of breast cancer that has receptors for estrogen or progesterone, making it responsive to hormone therapy.
  • In vitro fertilization (IVF): A complex series of procedures used to help with fertility or prevent genetic problems and assist with the conception of a child.
  • Ovulation induction: The stimulation of ovulation using medication, often used in fertility treatments.
  • Tamoxifen: A medication used to treat hormone receptor-positive breast cancer by blocking the effects of estrogen in breast tissue.
  • Disease-free survival: The length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer.
  • Neoadjuvant therapy: Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery.
  • Gonadotropins: Hormones that stimulate the ovaries or testes, often used in fertility treatments.
  • Estradiol: The primary form of estrogen in the human body, important in female reproductive health and development.

References

  1. https://clinicaltrials.gov/study/NCT02679755
  2. https://clinicaltrials.gov/study/NCT01740427
  3. https://clinicaltrials.gov/study/NCT00333086
  4. https://clinicaltrials.gov/study/NCT04421547
  5. https://clinicaltrials.eu/trial/study-of-pf-07220060-and-letrozole-for-postmenopausal-women-with-hr-positive-her2-negative-breast-cancer/
  6. https://clinicaltrials.gov/study/NCT02142868